BeiGene released its 2023 Responsible Business and Sustainability report, announcing global progress

The 2023 annual report details the company's achievements and future plans in terms of sustainable development

BEIJING, China, Cambridge, Massachusetts, and Basel, Switzerland, April 26, 2024 /PRNewswire/ -- BeiGene Limited (NASDAQ: BGNE, HKEX: 06160; SSE: 688235), a global oncology innovator, today released its 2023 Responsible Business and Sustainability report, highlighting its strategy, the progress it has made against its current goals, and how it can achieve more aggressive new goals in the future.

At the time of the report's release, BeiGene's global business was also growing rapidly. In 2023, the company achieved a milestone in the cumulative number of patients worldwide who were treated with the BTK inhibitor brukinsa ® (zanubrutinib) and the anti-PD-1 antibody tislelizumab ®. In addition, the company is actively expanding its global footprint, including our flagship manufacturing facility and clinical development center at the Princeton West Innovation Campus in Hopewell, New Jersey, USA, which is expected to open in July this year.

John V. Oyler, co-founder, chairman and chief executive officer of BeiGene, said, "Cancer patients have the right to access high-quality, impactful medicines, regardless of their location or socioeconomic status. But there are still many patients who have to wait years to get the drug, or simply can't afford it. Since its founding, BeiGene has believed that there is a better way to reduce these barriers and expand the reach and impact of our medicines, which is why we have strategically built our company. We strive to bring medicines to more people, faster, in a more cost-effective way. Our commitment to innovation goes far beyond working in the lab. As a leading global oncology innovator and committed to being a good corporate citizen, BeiGene understands that we need to go the extra mile for our patients, employees, stakeholders, and the communities in which we operate. "

BeiGene's Responsible Business and Sustainability strategy is structured around four focus areas: advancing global health, empowering employees, sustainable innovation, and operating responsibly. Since 2021, BeiGene has been committed to setting targets in each area and reporting on progress annually.

Key Achievements:

BeiGene's Responsible Business and Sustainability report highlights key results the company has achieved since 2023, including:

• The proportion of women in VP and above positions increased from 33% in 2022 to 38% in 2023.
• A Global Health Equity Strategy has been developed.
• More than 20,000 hours of employee volunteer service worldwide.
• Integrate climate risk into our enterprise risk management processes.
• Launch of a supplier management program that will help BeiGene achieve Scope 3 target setting by 2025.

Set the first quantitative climate target

BeiGene understands that human health is inextricably linked to the health of the planet. As a business focused on improving health and promoting health equity, the company is committed to reducing the environmental impact of its operations.

In 2023, BeiGene announced its first quantitative climate goal: by 2026, BeiGene's Scope 1 and Scope 2 emissions (emissions from owned and operated facilities) per unit of self-produced goods will be reduced by 25% from 2021 levels.

To meet its climate goals, BeiGene is implementing strategic plans that include energy efficiency enhancement projects such as installing solar panels at its manufacturing sites and renewable energy procurement projects.

Expand access to patients around the world

Founded in early 2023 as an independent 501(c)(3) nonprofit organization, BeiGene Foundation is committed to removing barriers to equitable and accessible cancer treatment for underserved communities around the world. As part of the first year of their partnership, BeiGene Foundation and the Max Foundation will provide BRUKINSA ® to adults with chronic lymphocytic leukemia in 29 low- and middle-income countries around the world over the next three years. The collaboration will combine the Max Foundation's expertise and infrastructure with BeiGene's drug donation and funding from the BeiGene Foundation to advance both companies' efforts to improve access to medicines for patients.

Christine Riley Miller, Global Head of Responsible Business and Sustainability, BeiGene, said, "We are proud that we have made so much progress in our focus areas in just a few years. As BeiGene continues to grow, our responsibilities grow with each passing day. We need to maximize positive change and minimize the negative impact on our business, society and the planet. We look forward to continuing on this path. "

To learn more about BeiGene's strategy, results, and goals for responsible business and sustainability, click here to access the report.

About BeiGene:

BeiGene is a global oncology innovation company focused on developing innovative oncology drugs for cancer patients around the world. Through strong independent R&D capabilities and external strategic partnerships, we continue to accelerate the development of diversified and innovative drug pipelines and product portfolios, and are committed to comprehensively improving drug accessibility and affordability for more patients around the world. We have a team of more than 10,000 people on five continents and have major offices in Beijing, Cambridge, Massachusetts, and Basel, Switzerland. For more information, please visit or follow BeiGene on WeChat.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including BeiGene's future growth and global expansion, BeiGene's ability to meet the goals set forth in its 2023 Responsible Business and Sustainability Report, and BeiGene's plans referred to under the heading "About BeiGene," Commitments, aspirations, and goals. Actual results may differ materially from those in the forward-looking statements as a result of a variety of important factors. These factors include: BeiGene's ability to demonstrate the efficacy and safety of its drug candidates, the fact that the clinical results of the drug candidates may not support further development or marketing approval, the actions of the regulatory authorities that may affect the initiation, timeline and progress of clinical trials and drug marketing approvals, BeiGene's ability to commercially succeed its marketed drugs and, if approved, BeiGene's ability to obtain and maintain intellectual property protection for its drugs and technologies, and BeiGene's reliance on third parties for drug development, manufacturing, commercialization and other services, BeiGene's limited experience in obtaining regulatory approvals and commercializing medicinal products and its ability to obtain further working capital to complete the development of drug candidates and to achieve and maintain profitability, as well as the risks discussed more fully in the "Risk Factors" section of BeiGene's most recent Annual Report on Form 10-K, and BeiGene's discussion of potential risks, uncertainties and other important factors in BeiGene's subsequent filings with the Securities and Exchange Commission. All information in this press release is current only as of the date of this press release, and BeiGene undertakes no obligation to update such information except as required by law.